Targeting a key protein in Ewing sarcoma to improve treatment outcomes
The interface of transcription, DNA damage and epigenetics: A therapeutic vulnerability of the EWS-FLI1 transcription factor
This study is looking at new ways to treat Ewing sarcoma by testing a combination of two medicines, trabectedin and irinotecan, to see how well they work together and why some patients might not respond, with the goal of making treatment more effective and easier on patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11077804 on NIH RePORTER |
What this research studies
This research focuses on Ewing sarcoma, a type of cancer that relies on the EWS-FLI1 transcription factor for survival. The team aims to develop new therapies that inhibit this protein, particularly using a compound called trabectedin in combination with irinotecan. By studying how these treatments work and why some patients experience resistance, the researchers hope to enhance the effectiveness of the therapy and reduce side effects. This approach could lead to better management of Ewing sarcoma and improved patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Ewing sarcoma, particularly those whose tumors express the EWS-FLI1 transcription factor.
Not a fit: Patients with Ewing sarcoma who do not have the EWS-FLI1 mutation or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with Ewing sarcoma, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting oncogenic transcription factors, indicating potential for success in this area.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Grohar, Patrick J — University of Michigan at Ann Arbor
- Study coordinator: Grohar, Patrick J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.